Listen ⚡️ DeSci Ep. #4 | Decentralizing Drug Development—with Paul Kohlhaas & Tyler Golato of Molecule

 

“Science as a practice is inherently meant to be decentralized. Science is meant to be open. Decentralized science is new in the context of how it's being described, but how I would define decentralized science as basically building the tools to help make open science more possible. And open science is something that has existed for decades.” — Tyler Golato

Listen to this Episode Here:

ABOUT THIS EPISODE

Under the current centralized system, drug development happens in silos. Pharmaceutical companies don’t share information. Scientists run the same failed experiments over and over again. And the process of bringing a drug to market typically takes ten-plus years. But Paul Kohlhaas and Tyler Golato are building a new way to do drug development. A system that allows for collaboration and dramatically increases the speed of breakthroughs in healthcare.

CEO Paul and CSO Tyler are the Cofounders of Molecule, a decentralized biotech protocol that establishes a Web3 marketplace for research-related intellectual property.

 On this episode of Boost VC, Paul and Tyler join us to explain how their personal experiences with the failures of healthcare inspired their interest in changing the system. They discuss Molecule's end-to-end ecosystem for bringing drugs to market, describing how their IP-NFT both protects innovation and makes it more open, sharable and collaborative.

Listen in for insight on Eroom's Law and learn how open science leads to enormous efficiency gains in the drug development process.

Topics Covered

How Paul & Tyler define science

  • Empirical discovery of knowledge

  • Progressive search for truth

What inspired Paul & Tyler’s interest in science

  • Personal experience with failures of healthcare

  • Potential for DeSci to foster new behaviors

 Paul & Tyler’s failed experiment with crowdfunding

  • Tried to raise money for microdosing study

  • Partnership with University of Toronto

How Molecule has evolved since 2019

  • Ecosystem for bringing drugs to market

  • IP-NFT framework for collaboration

 How to make scientists more open to sharing

  • Improve user experience

  • Streamline funding process

The power of Molecule’s IP-NFT framework

  • Intellectual property rights held on chain

  • Collectively owned by patients

The value prop for open science

  • Creates enormous efficiency gains

  • Makes drug development much cheaper

Jack Scannel’s naming of Eroom’s Law

  • Technology to discover drugs improving

  • Yet drug discovery output in decline

The goals for DeSci over the next decade

  • Extend quality of human health span

  • Make science self-sovereign, self-aware

How Paul & Tyler define success

  • Remain true to values and vision for life

  • Net positive impact on every person

Connect with Paul Kohlhaas & Tyler Golato

 

Resources

Adam Draper

Managing Director at @BoostVC // Seed investor in @Coinbase, @Amplitude_HQ, @Benchling, Wave Mobile Money // Board Member of @Skybound I like comic books. #Bitcoin

 
Adam DraperPodcast, All